Counseling Points Multiple Sclerosis - Spring 2015 - 2
FACULTY: Series Editor Amy Perrin Ross, APN, MSN, CNRN, MSCN Neuroscience Program Coordinator Loyola University Medical Center Maywood, IL Counseling Points™ Encouraging Monitoring and Follow-up in MS Care Faculty Panel Beverly A. Layton RN, CCRC, MSCN Multiple Sclerosis Nurse Consultant Birmingham, AL Continuing Education Information Marie Moore, FNP Nurse Practitioner CMC-Multiple Sclerosis Center Charlotte, NC This educational activity is designed to meet the needs of nurses who treat or who have an interest in patients with multiple sclerosis (MS). Valerie Stickel-Diehl, RN, MS, MSCN Nurse Case Manager Mercy Ruan Neuroscience Center Des Moines, IA To provide nurses who treat patients with MS with information and practice advice related to safety monitoring and follow-up associated with MS disease-modifying therapies. Faculty Disclosure Statements Amy Perrin Ross has received honoraria for participating on the Speakers' Bureaus for Acorda, Bayer HealthCare, Inc., Biogen Idec, EMD Serono, Genzyme, Mallinckrodt, Novartis, Pfizer, and Teva Pharmaceuticals, and as a consultant for Acorda, Bayer HealthCare, Inc., EMD Serono, Genzyme, Mallinckrodt, Novartis, and Teva Pharmaceuticals. Marie Moore has received honoraria for participating on the Speakers' Bureaus for Biogen Idec, Genzyme, Novartis, and Pfizer. Beverly Layton has received honoraria for participating on the Speaker's Bureaus for Biogen Idec, Genzyme, and Pfizer; consulting for Bayer, Genzyme, Novartis, and Questcor; and from Biogen Idec for research support. Valerie Stickel-Diehl has received honoraria for participating on the Speakers' Bureaus for Acorda Therapeutics, Biogen Idec, Genzyme, Novartis, and Pfizer. Planners and Managers The following planners and managers have declared no relevant financial relationships: Joseph J. D'Onofrio, Frank Marino, Katherine Wandersee. PUBLISHING INFORMATION: Publishers Joseph J. D'Onofrio Frank M. Marino Delaware Media Group 66 South Maple Avenue Ridgewood, NJ 07450 Tel: 201-612-7676 Fax: 201-612-8282 Websites: www.delmedgroup.com www.counselingpoints.com Medical Writer Katherine Wandersee Art Director James Ticchio Cover photo credits: © StockPhotosArt.com / Veer; Thomas Pajot / Veer; PicsFive / Veer; cienpies / Veer; Alloy Photography / Veer Copyright © 2015, Delaware Media Group, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, or Teva Pharmaceuticals. www.counselingpoints.com Target Audience Purpose Learning Objectives Upon completion of this educational activity, the participant should be able to: * Discuss current challenges associated with pre-treatment monitoring for MS disease-modifying therapies (DMTs) * Assess methods for recommending and encouraging regular follow-up while on MS DMT * Review how appropriate monitoring can prevent complications of MS DMTs Continuing Education Credit This continuing nursing education activity is developed under the joint providership of Delaware Media Group and NP Alternatives. NP Alternatives is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Laurie Scudder, DNP, NP, served as nurse planner and reviewer for this activity. She has declared no relevant financial relationships. This activity has been awarded 1.0 contact hours (1.0 contact hours are in the area of pharmacology). Code: MSCP04015. In order to earn credit, please read the entire activity and complete the post-test and evaluation at the end. Approximate time to complete this activity is 60 minutes. This program expires April 1, 2017. Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. Teva Pharmaceuticals and Delaware Media Group do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Teva Pharmaceuticals and Delaware Media Group. Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities. 2